← Back to Treatments
🏅 FDA Orphan Designation

TRETTEN

coagulation factor XIII A-subunit (recombinant)

Manufacturer: Novo Nordisk, Inc.

Indicated for:
Moderate hemophilia AOrphanCongenital factor XIII deficiencyOrphan

FDA-Approved Indications (2)

Moderate hemophilia AOrphan Designation

Routine prophylaxis of bleeding in patients with congenital Factor XIII A-subunit deficiency.

Routine prophylaxis of bleeding in patients with congenital Factor XIII A-subunit deficiency

Population: all ages

Indications & Usage

Routine prophylaxis of bleeding in patients with congenital Factor XIII A-subunit deficiency.

Medical disclaimer: This information is for educational purposes only. Always consult a qualified healthcare provider before making treatment decisions. Data sourced from FDA and current as of our last update.